Lenalidomide (CC-5013)

製品コードS1029

カスタマーフィードバック(4)

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure.

    Clin Cancer Res, 2011, 17(10): 3259–71. Lenalidomide (CC-5013) purchased from Selleck.

     

    Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α.

    Obesity 2012 20, 2174-85. Lenalidomide (CC-5013) purchased from Selleck.

  • MM1S were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 72 hours. Annexin/PI staining show increased apoptosis associated with caspase 8 and PARP cleavage after 18 and 36 hours of exposure. B) MM.1S cells were treated with AT9283 (0.125 μM), lenalidomide (2 μM) or combined therapy for 4 hours. Whole lysates were immunoblotted with indicated antibodies

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

    MM.1S cells were cultured for 48 hours in the presence or absence of BMSCs with control media, AT9283, lenalidomide or  AT9283 plus lenalidomide. Cell proliferation was assessed by 3H-TdR uptake (left). MM.1S cells were cultured in the absence or presence of BMSCs and treated for 4 hours with drugs alone or in combination. Whole lysates were immunoblotted with indicated antibodies.

     

     

    Harvard Medical School. Lenalidomide (CC-5013) purchased from Selleck.

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Lenalidomide (CC-5013)は一種のTNF-α分泌阻害剤で、PBMCsの中にIC50値が13 nMです。
靶点
TNF-α [1]
(PBMCs)
13 nM
In vitro試験

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC M3zGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwMUWwN|gh|ryP MmXoV2FPT0WU
L-363 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DWbmlEPTB;Mj65NlIyOiEQvF2= MXzTRW5ITVJ?
JAR MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfWTWM2OD1{Lkm3NFAyKM7:TR?= MkC1V2FPT0WU
EoL-1-cell NHnWNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4R2lEPTB;ND6xNFUyPSEQvF2= NV[wbppCW0GQR1XS
BT-549 M1ywNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFTWM2OD14LkKxPFQ6KM7:TR?= MYDTRW5ITVJ?
SK-NEP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf0TWM2OD15Lki5OVEzKM7:TR?= NW\4TIFTW0GQR1XS
BV-173 NHWyUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThwNke1PFUh|ryP MWHTRW5ITVJ?
HMV-II NYPUS4x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvCTlRKSzVyPUGwMlAyPzJizszN NXPMUlZxW0GQR1XS
HCC1806 NUHHOZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;YTWM2OD1zMT60OFY4KM7:TR?= MXXTRW5ITVJ?
KASUMI-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTLZmVnUUN3ME2xNU42PzFizszN MoL2V2FPT0WU
SK-MEL-28 NFHRbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX2TWM2OD1zMT65O|Y1KM7:TR?= NF\6N5lUSU6JRWK=
RPMI-8226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWzTWM2OD1zMj62NlQyKM7:TR?= MkT4V2FPT0WU
T47D M2r1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnkSGJKSzVyPUGzMlIxQTlizszN M3XSUXNCVkeHUh?=
HOP-62 NF3aUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PqSmlEPTB;MUOuOFgh|ryP MV;TRW5ITVJ?
A2058 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknoTWM2OD1zMz64NVk6KM7:TR?= NVHkOnRIW0GQR1XS
SW620 NUX4WHk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXiT2d5UUN3ME2xOE4zPDd|IN88US=> MkTyV2FPT0WU
LCLC-103H MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkS4PVIh|ryP NVrMSm5JW0GQR1XS
HAL-01 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHGTWM2OD1zND61O|k3KM7:TR?= NVL0elN3W0GQR1XS
PANC-08-13 NV3Zb45DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD1zND65NVA5KM7:TR?= MmPEV2FPT0WU
COLO-684 M2f5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF3LkO5O|kh|ryP MVXTRW5ITVJ?
DEL NFPEWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLFflhKSzVyPUG1MlQ6QSEQvF2= M{n3VXNCVkeHUh?=
K5 NH60[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLBTGlKSzVyPUG2MlE1QDZizszN NY\jZVJIW0GQR1XS
SK-MEL-24 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkS2OVIh|ryP M3Pi[3NCVkeHUh?=
ACN Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTBTWM2OD1zNj61Nlk4KM7:TR?= MV;TRW5ITVJ?
H9 NIi0b4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\UTmlEPTB;MU[uOlI3KM7:TR?= Mlz3V2FPT0WU
EM-2 NXv6OYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DiNWlEPTB;MUeuNVQ{KM7:TR?= NH;BWYRUSU6JRWK=
HSC-4 NXjkPWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMfFFKSzVyPUG3MlY3ODFizszN NWDmNFVRW0GQR1XS
IGROV-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF5Lke4N{DPxE1? NH;lO|hUSU6JRWK=
TE-1 M2fxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GwSmlEPTB;MUeuPVk3QCEQvF2= Mn:zV2FPT0WU
LN-405 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjtO|F3UUN3ME2xPU46ODd4IN88US=> NHHvbFFUSU6JRWK=
MSTO-211H M3fRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJyLkO1O|Mh|ryP Ml3kV2FPT0WU
MOLT-4 M4HGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD6SVJsUUN3ME2yNE42PzV7IN88US=> MWHTRW5ITVJ?
RS4-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf0TWM2OD1{Mj6xOVY{KM7:TR?= M3\YfHNCVkeHUh?=
ES3 NELOVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD1{Mj62PVY{KM7:TR?= MUjTRW5ITVJ?
SBC-1 NUXzUYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXaXXZKSzVyPUKzMlg3QTZizszN MVrTRW5ITVJ?
CTV-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ3LkCxOFkh|ryP NFnBdYNUSU6JRWK=
HuP-T3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonCTWM2OD1{NT60NFA6KM7:TR?= M4[0bnNCVkeHUh?=
HCC2218 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSxXXV1UUN3ME2yOU42PDB5IN88US=> MXfTRW5ITVJ?
HDLM-2 M4r6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7rTWM2OD1{OD6yNFI3KM7:TR?= MYLTRW5ITVJ?
ABC-1 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ7Lk[5O|Qh|ryP NFvPd4dUSU6JRWK=
MV-4-11 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPMUnA{UUN3ME2yPU44OzF5IN88US=> NH3iRoFUSU6JRWK=
WM-115 NVfmV|hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj2coZKSzVyPUOwMlMxQTlizszN NH\HR5FUSU6JRWK=
SW1990 M330TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkezTWM2OD1|MD6zN{DPxE1? MX3TRW5ITVJ?
HCC70 M4PTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HofmlEPTB;M{CuO|M1PiEQvF2= MlfHV2FPT0WU
KYSE-520 NX\WTZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXUXWhKSzVyPUOwMlg5OzlizszN MWXTRW5ITVJ?
JEG-3 NX74c45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHQXlVTUUN3ME2zNU4yPjF2IN88US=> MVXTRW5ITVJ?
C8166 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL0N4ZxUUN3ME2zNU4zOjd2IN88US=> NW\CPHBCW0GQR1XS
SK-OV-3 NHG2b3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG5Ro1KSzVyPUOxMlY4PTVizszN M3LIfnNCVkeHUh?=
NCI-H526 NF\tZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv0U3dlUUN3ME2zNk43QDNizszN NX3MdIxXW0GQR1XS
NKM-1 NH:1c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN{Lkm1Olgh|ryP MWnTRW5ITVJ?
ECC10 NH3Eb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN2Lke0OFMh|ryP M4jtTnNCVkeHUh?=
A2780 M3WxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHzcnI1UUN3ME2zOU4{PjBzIN88US=> MmOxV2FPT0WU
KY821 MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33TTmlEPTB;M{WuO|Y5OSEQvF2= NEfYVo1USU6JRWK=
MKN1 NWXIPW9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\TTWM2OD1|Nj6yNVM4KM7:TR?= NGHmVYRUSU6JRWK=
EKVX MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG5cmdNUUN3ME2zO{41OjF{IN88US=> NH\ifXpUSU6JRWK=
EW-16 Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3aU|hKSzVyPUO4MlM5QDVizszN MUDTRW5ITVJ?
CTB-1 MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN7Lke3PFkh|ryP MnL6V2FPT0WU
COR-L105 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlryTWM2OD12MD60O|Q3KM7:TR?= MknNV2FPT0WU
NCI-SNU-5 M136Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRzLkKwOlkh|ryP NVHEfFZpW0GQR1XS
Mewo MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRzLkm4O|Eh|ryP MWXTRW5ITVJ?
BCPAP NX:ySnk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkTWM2OD12Mz63PVE4KM7:TR?= NYn5SmRxW0GQR1XS
KARPAS-45 NHqxXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTR2LkK3O|Yh|ryP NGrGTHNUSU6JRWK=
NCI-H1693 M4jlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S1Z2lEPTB;NE[uOlk5PiEQvF2= M2\tfnNCVkeHUh?=
H-EMC-SS Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHQTWM2OD12OD6zNlI1KM7:TR?= Ml7oV2FPT0WU
697 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZO2lEPTB;NUCuN|U1PSEQvF2= MWfTRW5ITVJ?
KP-N-YS M{OxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMPZFQUUN3ME21Nk4{OTR{IN88US=> NIDCN4dUSU6JRWK=
NCI-H1304 M4LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG3ZZNKSzVyPUWyMlcxOjRizszN MWfTRW5ITVJ?
NOS-1 M1X2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CwNmlEPTB;NUKuPFU2QSEQvF2= MWnTRW5ITVJ?
NCI-H2342 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTV|LkC1NFgh|ryP M1HINnNCVkeHUh?=
KYSE-270 NYPxbpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2facmlEPTB;NUOuOlM3PCEQvF2= MV;TRW5ITVJ?
LU-135 NFvnc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\wR5RKSzVyPUW1MlE5PTNizszN MofzV2FPT0WU
OE33 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XnS2lEPTB;NUWuPFE5KM7:TR?= NVn1d3dmW0GQR1XS
ML-2 M3HhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e4SGlEPTB;NUWuPVQ5QSEQvF2= MoS5V2FPT0WU
KMOE-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTV4LkK4PVMh|ryP NYTxSFF[W0GQR1XS
Daoy MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CwTmlEPTB;NU[uN|IxPCEQvF2= NVfr[FR{W0GQR1XS
KNS-62 M3rSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3OTWM2OD13Nz6wNVQzKM7:TR?= MYLTRW5ITVJ?
NBsusSR NXjndmhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17mbmlEPTB;NUeuOVcxPSEQvF2= NHjvU|hUSU6JRWK=
UACC-257 NFHjSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1SmlEPTB;NUiuOlI3PCEQvF2= MmXxV2FPT0WU
LU-139 Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTV6LkiyOkDPxE1? M1vZenNCVkeHUh?=
CAL-85-1 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTV6Lki2OFMh|ryP NXvvXHNSW0GQR1XS
NCI-H720 M4fWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTV6Lki5OFIh|ryP NWP1b45UW0GQR1XS
MLMA NGHpcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTV7LkC5NUDPxE1? NUDHPG1nW0GQR1XS
A3-KAW MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnnO2hUUUN3ME21PU4zQDB7IN88US=> NXfIOnNTW0GQR1XS
Ramos-2G6-4C10 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\iTWM2OD13OT62Nlg4KM7:TR?= NYTiOGRXW0GQR1XS
A388 NEm1OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTZyLkS0PUDPxE1? NGPlO3NUSU6JRWK=
LAMA-84 NW\1fHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jWNWlEPTB;NkCuPVkxPSEQvF2= NHXzZm5USU6JRWK=
GCT NIC5RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7xU3NKSzVyPU[xMlA4QDZizszN NYDyO4hpW0GQR1XS
K-562 M{H2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr5TWM2OD14MT61N|M{KM7:TR?= MnPxV2FPT0WU
NCI-H1666 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXYPWM4UUN3ME22NU45PzVizszN M4KwcnNCVkeHUh?=
NCI-H1993 M4[wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\USGlEPTB;NkOuOFA1OyEQvF2= M2jn[nNCVkeHUh?=
NCI-H358 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4S5UxUUN3ME22OU4xOTJzIN88US=> MmLSV2FPT0WU
NB6 NF70PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPiTWM2OD14NT65PFgh|ryP MUDTRW5ITVJ?
HCE-T NIKwVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTHTWM2OD14Nz6wO|k5KM7:TR?= MmPBV2FPT0WU
DOK NHLPd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTZ5LkS5OFgh|ryP NUnVc5FlW0GQR1XS
HT-1376 NHT2SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rLNmlEPTB;NkmuPFMyPCEQvF2= Mlj5V2FPT0WU
NEC8 NIPoclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\MSZlKSzVyPUewMlEzPDNizszN NGe5eodUSU6JRWK=
G-402 M3TaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojjTWM2OD15MD65N|k2KM7:TR?= NYL2ZmJ6W0GQR1XS
GR-ST M2PYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrNTWVxUUN3ME23NU4yPzJizszN MUDTRW5ITVJ?
QIMR-WIL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdzLkS0N|Qh|ryP NUi4RZhGW0GQR1XS
CHP-212 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\tTWM2OD15MT65OlUh|ryP Ml;0V2FPT0WU
KU812 MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTd{Lkm3NFIh|ryP NYC1bFk6W0GQR1XS
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTBUlRKSzVyPUezMlE1QDlizszN MV\TRW5ITVJ?
ChaGo-K-1 NIXERmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;GTWM2OD15ND63OFg3KM7:TR?= Ml\rV2FPT0WU
A498 NYC0Um1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELlWHZKSzVyPUe0Mlk{ODhizszN MlHsV2FPT0WU
NCI-H69 M12zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPw[oRKSzVyPUe1Mlc3PjNizszN M3juS3NCVkeHUh?=
NCI-H209 NHHpPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTd6Lk[xOFch|ryP MX7TRW5ITVJ?
CAL-33 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjIdpZMUUN3ME23PE46QTN7IN88US=> MojiV2FPT0WU
COLO-680N Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC4cWNKSzVyPUe5MlExODdizszN NVvBTZVMW0GQR1XS
D-283MED M2X0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HTTGlEPTB;N{muPFEzKM7:TR?= M1jJZXNCVkeHUh?=
ATN-1 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37nbmlEPTB;OEGuNVE5PyEQvF2= NYT5bHlSW0GQR1XS
NCI-N87 NH;xOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\4TWM2OD16MT63Nlk3KM7:TR?= MlfJV2FPT0WU
MHH-NB-11 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf3fJd6UUN3ME24NU45QDR7IN88US=> NWrMUnJIW0GQR1XS
HEL NH[xV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vSWmlEPTB;OEKuOFE{PCEQvF2= NEHmNWhUSU6JRWK=
NB69 NUfDSVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjsfGtKSzVyPUizMlAxOzNizszN MVnTRW5ITVJ?
MPP-89 NXny[VgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTh|LkK1O|Uh|ryP MmfOV2FPT0WU
COLO-829 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD16NT60PVEzKM7:TR?= NUPaVmJMW0GQR1XS
ONS-76 NUnEN4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv1TWM2OD16NT63PVA5KM7:TR?= NGK2SHJUSU6JRWK=
EW-3 M17hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorkTWM2OD16Nj6yNFMzKM7:TR?= M1XUdHNCVkeHUh?=
EW-11 M4H1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\rTWM2OD16Nj60N|M3KM7:TR?= NFX4NphUSU6JRWK=
SW900 M4\kdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz1N3N1UUN3ME24O{4zODV|IN88US=> MV7TRW5ITVJ?
MOLT-13 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO4Rm9KSzVyPUi3MlIzPDNizszN NW\Ne3R{W0GQR1XS
HuP-T4 NIDTXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK2UoZKSzVyPUmxMlA1ODVizszN M3vWRnNCVkeHUh?=
HCC1419 NG\mTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPPc|ZGUUN3ME25NU43Ozd2IN88US=> MlS4V2FPT0WU
CAL-72 M{fw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwcHVKSzVyPUmyMlAzOTlizszN MXrTRW5ITVJ?
Mo-T M{DaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;qTWM2OD17Mj63Olk4KM7:TR?= MWjTRW5ITVJ?
OC-314 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTl{Lki4NlEh|ryP NXS3U2RYW0GQR1XS
BHT-101 NVzzO5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDhPVRKSzVyPUmzMlEh|ryP NUm5cWZwW0GQR1XS
EW-18 M2PNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTl|Lki0OlIh|ryP MYTTRW5ITVJ?
TE-12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDRVI9rUUN3ME25OE4{ODV3IN88US=> NXHnbJZkW0GQR1XS
MDA-MB-361 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr1TWM2OD17Nj6wOVE3KM7:TR?= NHTLeXhUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

プロトコル(参考用のみ)

動物実験:

[5]

+ 展開
  • 動物モデル: Adult male Sprague-Dawley rats bearing HUVECs cells
  • 製剤: 0.5% DMSO
  • 投薬量: 50 mg/kg and 250 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (200.57 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 30% PEG400+0.5% Tween80+5% propylene glycol 5 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 259.26
化学式

C13H13N3O3

CAS No. 191732-72-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02871219 Recruiting Follicular Lymphoma M.D. Anderson Cancer Center|Genentech, Inc. December 6, 2016 Phase 2
NCT00540007 Completed Hodgkin Disease Washington University School of Medicine|Celgene Corporation September 6, 2007 Phase 2
NCT01629082 Completed Myeldysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia|Bone Marrow Diseases|Neutropenia|Acute Myeloid Leukemia (AML) National Heart, Lung, and Blood Institute (NHLBI)|Celgene Corporation|National Institutes of Health Clinical Center (CC) June 5, 2012 Phase 1
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT02225275 Recruiting Leukemia M.D. Anderson Cancer Center|Genentech, Inc.|Celgene Corporation March 31, 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What is the formulation for mouse injection(i.p.)?

  • 回答:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • 問題2:

    what is the procedure to resuspend this compound?

  • 回答:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

TNF-alpha信号経路図

TNF-alpha Inhibitors with Unique Features

相関TNF-alpha製品

Tags: Lenalidomide (CC-5013)を買う | Lenalidomide (CC-5013) ic50 | Lenalidomide (CC-5013)供給者 | Lenalidomide (CC-5013)を購入する | Lenalidomide (CC-5013)費用 | Lenalidomide (CC-5013)生産者 | オーダーLenalidomide (CC-5013) | Lenalidomide (CC-5013)化学構造 | Lenalidomide (CC-5013)分子量 | Lenalidomide (CC-5013)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID